News Genentech buys Regor's next-gen CDK inhibitors for $850M Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors to Roche's Genentech for an upfront cash payment of $850 million.
Oncology In pursuit of a cure for cancer: An ASCO 2025 discussion wit... Dr Danny Nguyen, medical oncologist and haematologist at the City of Hope Orange County, spoke with pharmaphorum at ASCO 2025.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face